No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

12/1

Regeneron

Tessera

Therapeutics

TSRA-196

Gene therapy

Metabolic

disorder

α1-antitrypsin deficiency

(AATD)

Preclinical

150

2

12/3

Laboratoires

Théa

Iolyx

ILYX-002

RIPK1 inhibitors

Ophthalmology

Dry eye

Phase 3

280

3

12/4

AstraZeneca

Neurimmune

NI009

αλLC fibrils mAb

Hematology

AL amyloidosis

Preclinical

780

4

12/8

Dr. Reddy’s
 Laboratories

Immutep

Eftilagimod

Alfa

LAG-3 agonist

Oncology

NSCLC

Phase 3

370

5

12/9

Novartis

Relation Therapeutics

Lab-in-the-

Loop platform

AI-driven platform to discover

novel targets

Immunology

Atopic diseases

-

1,700+

6

12/9

Pfizer

Shanghai Fosun
 Pharmaceutical

YP05002

GLP-1R agonist

Metabolic

disorder

Obesity

Phase 1

2,000+

7

12/10

Bleeker Bio
(Formation Bio)

Lynk

Pharmaceuticals

LNK01006

TYK2 allosteric inhibitor

Immunology

Multiple sclerosis

Preclinical

600

8

12/11

Zealand Pharma

OTR Therapeutics

n/d

Oral small molecule platform

Metabolic

disorder

n/d

n/d

2,500

9

12/15

Pfizer

Adaptive

Biotechnologies

-

Offender TCR target

discovery,

TCR-antigen datasets

Immunology

Rheumatoid arthritis

Discovery

n/d

10

12/15

Sanofi

ADEL

ADEL-Y01

αacetylated tau mAb

Neurology

Alzheimer's Disease

Phase 1

1,040

11

12/16

Yarrow

Bioscience

GenSci

(Changchun

GeneScience

Pharmaceutical)

GS-098
(YB-101)

αTSHR mAb

Immunology

Ophthalmology

Graves’ disease

Thyroid eye disease(TED)

Phase 1

Phase 1

1,365

12

12/16

Genentech

Caris Discovery

(Caris Life Sciences)

-

AI-driven platform to discover

novel targets

Oncology

-

-

1,100

13

12/18

Athira Pharma

Sermonix

Pharmaceuticals

Lasofoxifene

Oncology

Breast cancer

Phase 3

100

14

12/17

BMS

Harbour BioMed

Harbour Mice®

Fully human antibody

discovery/engineering

platform for next‑generation

MsAbs

-

-

-

1,125

15

12/21

AstraZeneca

Jacobio Pharma

JAB-23E73

Pan-KRAS inhibitor

Oncology

KRAS-mutated cancers

Phase 1

2,010

16

12/21

Windward Bio

Qyuns

Therapeutics

WIN027

TSLP x IL-13 BsAbs

Immunology

Asthma, Atopic dermatitis,
COPD

Phase 1

700

17

12/22

Ipsen

Simcere Zaiming

SIM0613

LRRC15 ADC

Oncology

Solid tumors

Preclinical

1,060

18

12/22

Boehringer

Ingelheim

Rectify

Pharmaceuticals

PFM platform

enhance ABCC6 protein

function

Genitourinary

Chronic kidney disease (CKD)

Preclinical

448

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

12/8

Mirum Pharmaceuticals

Bluejay Therapeutics

Brelovitug

αHBsAg mAb

Infectious diseases

Hepatitis D virus

Phase 3

820

2

12/19

BioMarin Pharmaceutical

Amicus Therapeutics

Galafold

Pombiliti+
Opfolda

DMX-200

GLA stimulants

Acid α‑glucosidase replacement +

UGCG inhibitor

Metabolic disorder

Metabolic disorder

Genitourinary

Fabry Disease

Pompe Disease

FSGS

Marketed

Marketed

Phase 3

4,800

3

12/24

Sanofi

Dynavax Technologies

HEPLISAV-B®

Z-1018

Vaccine

Vaccine

Infectious diseases

Infectious diseases

Hepatitis B virus

Varicella zoster virus

Marketed

Phase 1/2

2,200